Clinical Trials Directory

Trials / Conditions / Eosinophilic Granulomatosis With Polyangiitis

Eosinophilic Granulomatosis With Polyangiitis

13 registered clinical trials studyying Eosinophilic Granulomatosis With Polyangiitis — 4 currently recruiting.

StatusTrialSponsorPhase
UnknownThe Epigenomic Signature of Eosinophilic Granulomatosis With Polyangiitis
NCT06231498
Meyer Children's Hospital IRCCS—
RecruitingTrial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyan
NCT06046222
NS Pharma, Inc.Phase 2
RecruitingA Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Poly
NCT05979051
Guangdong Hengrui Pharmaceutical Co., LtdPhase 2 / Phase 3
Active Not RecruitingEfficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophil
NCT05263934
GlaxoSmithKlinePhase 3
Active Not RecruitingStudy of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic
NCT05030155
Assistance Publique - Hôpitaux de ParisPhase 3
CompletedMepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With
NCT04551989
GlaxoSmithKline—
CompletedPRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis
NCT04280601
Christian PagnouxN/A
CompletedNUCALA® Special Drug Use Investigation (EGPA, Long-term)
NCT03557060
GlaxoSmithKline—
CompletedMaintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Gran
NCT03164473
Assistance Publique - Hôpitaux de ParisPhase 3
RecruitingVCRC Tissue Repository
NCT02967068
University of Pennsylvania—
CompletedLong-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
NCT03298061
GlaxoSmithKlinePhase 3
UnknownPediatric Vasculitis Initiative
NCT02006134
University of British Columbia—
RecruitingLongitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
NCT00315380
University of Pennsylvania—